Cabaletta Bio (NASDAQ:CABA) Stock Rating Reaffirmed by Mizuho

Cabaletta Bio (NASDAQ:CABA – Get Rating)‘s stock had its “buy” rating reiterated by equities researchers at Mizuho in a report released on Friday, Benzinga reports. They currently have a $10.00 target price on the stock. Mizuho’s target price suggests a potential upside of 23.46% from the stock’s previous close.

CABA has been the topic of several other reports. Evercore ISI upped their price objective on shares of Cabaletta Bio from $14.00 to $18.00 in a research note on Thursday, February 16th. Wells Fargo & Company upped their target price on shares of Cabaletta Bio from $4.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. HC Wainwright upped their target price on shares of Cabaletta Bio from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Morgan Stanley upgraded shares of Cabaletta Bio from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $3.00 to $16.00 in a research report on Friday, January 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.17.

Cabaletta Bio Stock Up 4.5 %

Shares of Cabaletta Bio stock opened at $8.10 on Friday. Cabaletta Bio has a 1-year low of $0.59 and a 1-year high of $12.88. The firm’s 50-day moving average price is $9.67 and its two-hundred day moving average price is $5.54.

Hedge Funds Weigh In On Cabaletta Bio

Several large investors have recently bought and sold shares of CABA. UBS Group AG acquired a new position in Cabaletta Bio in the third quarter valued at approximately $33,000. Barclays PLC lifted its holdings in Cabaletta Bio by 239.6% in the fourth quarter. Barclays PLC now owns 4,146 shares of the company’s stock valued at $38,000 after buying an additional 2,925 shares during the period. Dynamic Technology Lab Private Ltd lifted its holdings in Cabaletta Bio by 81.6% in the first quarter. Dynamic Technology Lab Private Ltd now owns 19,250 shares of the company’s stock valued at $39,000 after buying an additional 8,648 shares during the period. Freedom Wealth Alliance LLC acquired a new position in Cabaletta Bio in the fourth quarter valued at approximately $41,000. Finally, Bank of New York Mellon Corp lifted its holdings in Cabaletta Bio by 120.2% in the first quarter. Bank of New York Mellon Corp now owns 22,674 shares of the company’s stock valued at $46,000 after buying an additional 12,379 shares during the period. 62.12% of the stock is currently owned by institutional investors and hedge funds.

Cabaletta Bio Company Profile

(Get Rating)

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.